Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

No link found between pneumonitis in breast cancer patients and taxane-based chemotherapies

17.11.2004


Researchers at The University of Texas M. D. Anderson Cancer Center have shown that breast cancer patients treated with taxane-based chemotherapies and radiation are not at increased risk of developing a dangerous lung condition involving the inflammation of lung tissue, pneumonitis, according to a study published in the Nov. 17 issue of the Journal of the National Cancer Institute.



These results are vitally important, says Thomas Buchholz, M.D., the study’s corresponding author, because both radiation and taxanes-based chemotherapies, including Taxotere and Taxol, have proven effective in the treatment and improved survival of selected patients with breast cancer. In addition, these results disprove a previous smaller study that had suggested the dangerous correlation between taxanes, radiation treatment and lung injury. "We had the unique opportunity to investigate and clearly focus on the question of whether or not taxanes increase radiation induced lung complications," says Buchholz, professor in the Department of Radiation Oncology at M. D. Anderson. "Both taxanes and radiation therapy are critically important in the treatment of patients whose disease has spread beyond the breast.

"The first study showed higher rates of toxicity and received a great deal of attention within the medical community. We were concerned that oncologists might have some reluctance in giving these appropriate treatments. With this study, we wanted to try and determine if we could alleviate the fears of both the physicians administering, and the patients receiving these potentially life-saving treatments."


The research, led by Tse-Kuan Yu, M.D., Ph.D., a resident in radiation oncology at M. D. Anderson and the study’s principal investigator, analyzed 189 breast cancer patients who had been enrolled in a prospective Phase III randomized trial. The patients had received either four cycles of paclitaxel (Taxol) followed by four cycles of 5-flourouracil, doxorubicin and clyclophsphamide (FAC) and then radiation therapy; or eight cycles of FAC followed by radiation.

The researchers were able to review chest X-rays of the women in both groups and could directly evaluate the rates of lung injury. They concluded that there was statistically no difference in the rate of radiation-induced lung toxicity between the two groups of patients; 5 percent in those treated with the paclitaxel-FAC and radiation, compared with 4.5 percent in those treated with FAC and radiation. In addition, the researchers reported that no patients were hospitalized and/or died as a result of pneumonitis. "Fortunately, we discovered that the rates of seriously related lung injury were very, very low in both groups of patients, making us more comfortable in using these potentially curative treatments without any reservations," says Buchholz.

Buchholz and Yu both point out a key difference between the M. D. Anderson research and the earlier study that suggested the lung damage correlation was, in the M. D. Anderson study, chemotherapy and radiation were given sequentially, compared to simultaneous delivery in the smaller study. "It is possible that taxanes and radiation given simultaneously interact to cause increased lung toxicity, but with our delivery, which is more standard practice, we did not see any clinically-relevant damage," says Yu. "Additionally, the sequencing and extended time between the delivery of paclitaxel and the radiation might be of great importance. In our study, four cycles of paclitaxel and then four cycles of FAC were given, followed by surgery and then radiation. Having the buffer window between the Taxol and the radiation might be, in part, cause for why we did not see any lung injury."

Other researchers collaborating on the M. D. Anderson study include: Gary J. Whitman, M.D.; Howard D. Thames, Ph.D.; Aman U. Buzdar, M.D.; Eric A. Strom, M.D.; George H. Perkins, M.D.; Naomi R. Schechter, M.D.; Marsha D. McNeese, M.D.; Shu-Wan Kau; Eva S. Thomas, M.D.; and Gabriel Hortobagyi, M.D.

Laura Sussman | EurekAlert!
Further information:
http://www.mdanderson.org

More articles from Health and Medicine:

nachricht Indications of Psychosis Appear in Cortical Folding
26.04.2018 | Universität Basel

nachricht GLUT5 fluorescent probe fingerprints cancer cells
20.04.2018 | Michigan Technological University

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Why we need erasable MRI scans

New technology could allow an MRI contrast agent to 'blink off,' helping doctors diagnose disease

Magnetic resonance imaging, or MRI, is a widely used medical tool for taking pictures of the insides of our body. One way to make MRI scans easier to read is...

Im Focus: BAM@Hannover Messe: innovative 3D printing method for space flight

At the Hannover Messe 2018, the Bundesanstalt für Materialforschung und-prüfung (BAM) will show how, in the future, astronauts could produce their own tools or spare parts in zero gravity using 3D printing. This will reduce, weight and transport costs for space missions. Visitors can experience the innovative additive manufacturing process live at the fair.

Powder-based additive manufacturing in zero gravity is the name of the project in which a component is produced by applying metallic powder layers and then...

Im Focus: Molecules Brilliantly Illuminated

Physicists at the Laboratory for Attosecond Physics, which is jointly run by Ludwig-Maximilians-Universität and the Max Planck Institute of Quantum Optics, have developed a high-power laser system that generates ultrashort pulses of light covering a large share of the mid-infrared spectrum. The researchers envisage a wide range of applications for the technology – in the early diagnosis of cancer, for instance.

Molecules are the building blocks of life. Like all other organisms, we are made of them. They control our biorhythm, and they can also reflect our state of...

Im Focus: Spider silk key to new bone-fixing composite

University of Connecticut researchers have created a biodegradable composite made of silk fibers that can be used to repair broken load-bearing bones without the complications sometimes presented by other materials.

Repairing major load-bearing bones such as those in the leg can be a long and uncomfortable process.

Im Focus: Writing and deleting magnets with lasers

Study published in the journal ACS Applied Materials & Interfaces is the outcome of an international effort that included teams from Dresden and Berlin in Germany, and the US.

Scientists at the Helmholtz-Zentrum Dresden-Rossendorf (HZDR) together with colleagues from the Helmholtz-Zentrum Berlin (HZB) and the University of Virginia...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

VideoLinks
Industry & Economy
Event News

Invitation to the upcoming "Current Topics in Bioinformatics: Big Data in Genomics and Medicine"

13.04.2018 | Event News

Unique scope of UV LED technologies and applications presented in Berlin: ICULTA-2018

12.04.2018 | Event News

IWOLIA: A conference bringing together German Industrie 4.0 and French Industrie du Futur

09.04.2018 | Event News

 
Latest News

World's smallest optical implantable biodevice

26.04.2018 | Power and Electrical Engineering

Molecular evolution: How the building blocks of life may form in space

26.04.2018 | Life Sciences

First Li-Fi-product with technology from Fraunhofer HHI launched in Japan

26.04.2018 | Power and Electrical Engineering

VideoLinks
Science & Research
Overview of more VideoLinks >>>